The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing Consortium, a ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...